Cantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating

Benzinga Newsdesk www.benzinga.com Positive 64.6%

Neg 0% Neu 0% Pos 64.6%

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating.